详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Robo1 CAR-NK92 and radiotherapy exert synergistic efficacy in solid tumors

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. [2]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin District, Jinan, 250117, Shandong, China. [3]Department of Oncology, The First People's Hospital of Yibin, Yibin, Sichuan, China. [4]Asclepius (Soochow) Technology Company Group, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, 215123, Jiangsu, China.

出处：

DOI：

关键词： Robo1 Chimeric antigen receptor Natural killer cells Radiation therapy Solid tumors Tumor microenvironment

摘要：

The efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in treating solid tumors is often limited, primarily due to the tumor microenvironment (TME), which hinders the recognition and infiltration of CAR-NK cells. Radiotherapy has been shown to modify the TME, enhance immune cell infiltration, and improve the recognition of tumor cells by immune cells. This study aimed to investigate the effects of combining radiotherapy with CAR-NK cells in a solid tumor model.The Robo1 CAR-NK92 cell line was developed to specifically target Robo1. Tumor cell lines were generated following radiotherapy, and the cytotoxicity and infiltration of Robo1 CAR-NK92 cells in solid tumor models were evaluated both in vitro and in vivo post-radiotherapy.The cytotoxicity of Robo1 CAR-NK92 cells against tumor cells was significantly enhanced following radiotherapy, likely due to the upregulation of NKG2D ligands on the surface of the tumor cells. Furthermore, tumor cells post-radiotherapy were found to promote the migration of Robo1 CAR-NK92 cells. In in vivo experiments, the combination of radiotherapy and Robo1 CAR-NK92 cells resulted in prolonged survival and improved tumor control in a solid tumor mouse model.Our results indicate that the combination of Robo1 CAR-NK92 therapy and radiotherapy may present a promising approach for the treatment of solid tumors.© 2025. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区

医学

小类 | 2 区医学：研究与实验

最新[2025]版：

大类 | 2 区

医学

小类 | 2 区医学：研究与实验

第一作者：

第一作者机构： [1]Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. [2]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin District, Jinan, 250117, Shandong, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential [2]嵌合抗原受体自然杀伤细胞免疫治疗多发性骨髓瘤研究进展 [3]Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. [4]A compound chimeric antigen receptor strategy for targeting multiple myeloma. [5]Requirements for human natural killer cells [6]Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives [7]Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy [8]GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. [9]Research advances in chimeric antigen receptor-modified T-cell therapy (Review). [10]Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy